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Abstract: AgOTf·Phosphoramidite complexes catalyze efficiently the enantioselective Mannich-
type reaction between benzophenone-imine glycine methyl ester and N-tosyl aldimines in the 
absence of base. The corresponding syn-adducts, which are direct precursors of α,β-diamino acids, 
are obtained in moderate to good syn-diastereoselectivities (up to 9:1) and high enantioselectivities 






The asymmetric Mannich reaction is a very useful methodology for the preparation of 
enantioenriched β-amino carbonyl compounds where the absolute configuration of two stereogenic 
centers can be defined simultaneously.1,2,3  There are many type of enolates which are able to add to 
imines by intermediacy of chiral metal complexes or organocatalysts. Interestingly, in  the case of 
using Schiff bases derived from α-amino esters 1 as nucleophiles and imines 2, protected α,β-
diamino esters 3 can be straightforwardly prepared. After deprotection α,β-diamino acids 4 are 
easily generated, which are biologically relevant4 and also chemically attractive due to their use as 
chiral building blocks5 (Scheme 1). Apart from this Mannich-type reaction, the asymmetric 
amination of α,β-unsaturated acid derivatives, and the catalytic hydrogenation of bis-







































Scheme 1. General Mannich-type reaction between imino esters and N-protected imines 
  
The enantioselective reaction of imino esters 1 with N-protected imines shown in Scheme 1 has 
been successfully performed in the presence of chiral organocatalysts 57a and 67b or chiral metal 
complexes 7-158 (Figure 1). The reactions involving organocatalysts 5 and 6 afforded almost 
exclusively the syn-3 diastereoisomer with excellent enantioselections.9 The syn-diasteroisomer was 
also the major isolated product when chiral copper complexes were employed. The unique 
exception was registered when the major anti-3 diastereoisomer was isolated in good 
enantioselectivities after the reaction with copper(I) complexes 11 and 12. In the case of aldimino 
esters 1 (R1 = H, R2 = Ph) the anti-3 diastereoisomers were isolated with excellent 
enantioselectivities, a bulky N-(8-quinolyl)sulfonyl protecting group being needed.8i Copper salts 
are mainly employed and only one contribution employed a chiral 15·silver acetate complex 































































































We have recently described that complexes formed by silver salts and privileged chiral ligands10 
such as Binap 1611 and phosphoramidites 17 and 1812 are excellent catalysts for enantioselective 
1,3-dipolar cycloadditions13,14 of azomethine ylides derived from imino esters 1 in the construction 
of enantiomerically enriched highly substituted prolines.15,16 In this work, we will describe the 
application of these silver chiral complexes17 in the Mannich type reaction of glycine benzophenone 

















Figure 2. Chiral privileged ligands 16-18 employed in this study. 
 
 
Results and Discussion 
 
The selected reaction for the optimization conditions involved the glycine benzophenone imine 
derivative 1a (R1 = R2 = Ph, R3 = H and R4 = Me), benzaldehyde N-tosylimine 2a (PG = Ts), 
triethylamine (5 mol%) as base, and AgOAc (5 mol%) in toluene as solvent at room temperature for 
1 d (Scheme 2). The reaction performed with (S)-Binap 16 was first evaluated in the presence and in 
the absence of triethylamine. High conversions and 67:33 syn:anti diastereomeric ratios of 
compound 3a were obtained in both cases. Surprisingly, the highest enantioselection was observed 
for the syn-diastereoisomer when no base was added (Table 1, entries 1 and 2). The same behavior 
was exhibited by the chiral catalyst formed by Monophos 17 and silver acetate. A higher 75:25 dr 
was observed but with lower enantioselections (Table 1, entries 3 and 4). Phosphoramidite 18 and 
AgOAc offered a higher enantioselectivity (80% ee) and 80:20 dr when the reaction was carried out 
in the absence of base in (Table 1, compare entries 5 and 6). Copper(I) and copper(II) triflates were 
also surveyed (not shown in Table 1) giving a complex crude reaction mixture (1H NMR) from no 
completed reactions. The reactions run under conditions shown in entries 5 and 6 became very slow 
at 0 ºC.  
Silver perchlorate was a suitable metal salt for phosphoramidite 18 affording major syn-
stereoisomer 3a in high conversion but with lower diastereoselection (72:28) than the observed for 
the reaction run with AgOAc (Table 1, compare entries 5 with 6, and 6 with 8). In light of all these 
tests the reaction with different silver salts was next essayed without triethylamine. Thus, AgTfa 
(Tfa = trifluoroacetate), AgOBz, AgSbF6, and Ag2CO3 did not improve the enantioselection 
generated by the employment of silver perchlorate (Table 1, entries 9-12). However, the best results 
were observed when AgOTf was employed as silver salt (Table 1, entry 13).  
In order to ameliorate the diastereoselectivity of the process gaining some enantioselection, 
different nitrogen protecting groups for the imines such as nosyl (p-nitrophenylsulfonyl, Ns) and N-
(8-quinolyl)sulfonyl (8-Q) were evaluated. In both cases conversions were high but the 
enantioselection was very poor (Table 1, entries 14, and 15), even when the tert-butyl 
(diphenylmethylene)glycinate was used (Table 1, entries 16-18).  
The influence of the solvent was also noticeable. Toluene was the best solvent whereas THF, Et2O, 
DCM, and MeCN furnished both lower dr and ee (Table 1, entries 19-22). The mechanism of this 
reaction would be very similar than the reported one for the asymmetric synthesis of polysubstituted 




































Scheme 2. Optimization reaction model. 
 
Table 1. Optimization reactions. 
Ent. AgX Ligand Base PG Yield (%)a dr (syn:anti)a ee (syn, anti)b 
1 AgOAc 16 TEA Ts 100 67:33 12, 20 
2 AgOAc 16 ___ Ts 100 67:33 24, 2 
3 AgOAc 17 TEA Ts 100 75:25 <10, <10 
4 AgOAc 17 ___ Ts 100 75:25 10, 6 
5 AgOAc 18 TEA Ts 90 80:20 12, 24 
6 AgOAc 18 ___ Ts 90 80:20 80, 10 
7 AgClO4 18 TEA Ts 100 86:14 12, rac. 
8 AgClO4 18 - Ts 75 72:28 92, 32 
9 AgTfa 18 - Ts 85 60:40 14, 12 
10 AgOBz 18 - Ts 100 75:25 78, 38 
11 AgSbF6 18 - Ts 85 60:40 64, 16 
12 Ag2CO3 18 - Ts 92 84:16 8, 4 
13 AgOTf 18 - Ts 94 72:28 96, 58 
14 AgOTf 18 - Nsc 100 90:10 24, 18 
15 AgOTf 18 - 8-Qd 90 72:28 6, 2 
16 AgOTfe 18 - Ts 95 80:20 4, 28 
17 AgOTfe 18 - Nsc 100 >96:4 56, rac. 
18 AgOTfe 18 - 8-Qd 85 86:14 10, 6 
19 AgOTff 18 - Ts 89 67:33 38, 6 
20 AgOTfg 18 - Ts 92 72:28 rac., rac. 
21 AgOTfh 18 - Ts 91 62:38 58, 86 
22 AgOTfi 18 - Ts 87 72:28 24, 40 
a Determined by 1H RMN of the crude reaction mixture. 
b Determined by HPLC using chiral columns. 
c p-Nitrophenylsulfonyl group (nosyl). 
d N-(8-quinolyl)sulfonyl group. 
e The corresponding tert-butyl ester was employed. 
f Reaction run in the presence of THF as solvent. 
g Reaction run in the presence of Et2O as solvent. 
h Reaction run in the presence of DCM as solvent. 
i Reaction run in the presence of MeCN as solvent. 
 
 
The scope of the reaction was investigated under the optimized reaction conditions using toluene as 
solvent at room temperature. The reaction catalyzed by the complex AgOTf·(Sa,R,R)-18 gave the 
same results than those reported by using (Ra,S,S)-18 ligand but obtaining the opposite enantiomeric 
form ent-3 (Table 2, entry 2). Different aldimines were prepared according to known methods and 
directly employed as electrophiles in the titled Mannich type reaction with imino ester 1a. In 
general, if a comparison is established between product 3a (Table 2, entry 1) and the different 3b-3l 
molecules, the presence of a substituent in the ortho-position in the arene moiety produced a 
lowering of the enantioselection of the corresponding major syn-3 diastereoisomers (Table 2, entries 
3-5). However, halogenated aryl groups provided the highest ee in these series (Table 2, entries 4 
and 5) with moderate diastereoselection. The m-ubstituted chloroarene in imine 2 moiety afforded 
the best diastereoselection of the whole study but again very low enantiomeric excess was found for 
both the syn- and anti-isomers 3e (Table 2, entry 6). The effect of the para-substitution was very 
similar to those observed in the examples run with ortho-substituted arenes, that means low ee for 
the examples whose substituents were different from halogenated atoms (Table 2, entries 7-11). In 
this case 4-fluoro and 4-bromoarenes gave 99% ee and 80% ee, of the major syn-diastereoisomers 
3h and 3j, respectively. Heterocyclic substituents bonded to the imino group were also good 
precursors for a high enantioselective Mannich-type addition. Thus, 2-furyl derivative afforded 92% 
ee of 3k and 2-thienyl surrogate furnished 78% ee of 3l with a 75:25 dr in both cases (Table 2, 
entries 12-13). Despite being the reaction completed, chemical yields were moderate due to the 


































Table 2. Scope of the Mannich-type reaction. 
Ent. Ar 2  3 Yield (%)a dr (syn:anti)a ee (syn, anti)b 
1 Ph 2a  3a 70 72:28 96, 58 
2 Phc 2a  3a 70 72:28 -96, -58 
3 2-MeC6H4 2b  3b 50 80:20 14, 4 
4 2-ClC6H4 2c  3c 55 56:44 46, <5 
5 2-BrC6H4 2d  3d 67 60:40 48, 34 
6 3- ClC6H4 2e  3e 42 90:10 14, 14 
7 4-(CF3)C6H4 2f  3f 30 75:25 15, 2 
8 4-(NO2)C6H4 2g  3g 47 70:30 20, 12 
9 4-FC6H4 2h  3h 48 70:30 99, 10 
10 4-ClC6H4 2i  3i 30 70:30 42, 16 
11 4- BrC6H4 2j  3j 35 50:50 80, 10 
12 2-furyl 2k  3k 45 75:25 92, 24 
13 2-thienyl 2l  3l 45 75:25 78, 38 
a Isolated yield after column chromatography. 
b Determined by HPLC using chiral columns. 
c Reaction performed in the presence of AgOTf·(Ra,S,S)-18. 
 
This Mannich type reaction can be rationalized on the basis of the models proposed by different 
authors.8f The freshly generated azomethine ylide is coordinated by silver atom and the 
nucleophilic attack occurs to the tosyl imine whose arylsulfonyl group is placed far away from the 
benzylidene moiety of the dipole (Figure 3). In this transition state an additional coordination 

































The chiral complex formed by phosphoramidite 18 and AgOTf (1:1 molar ratio) was the most 
effective catalyst in the Mannich-type reaction between imino esters derived from benzophenone 
and N-tosylimines. No extra base was needed for the reaction completion, so it acted firstly as 
Lewis acid coordinating the imino ester and the corresponding counteranion has the base role 
required for the α-deprotonation.  Both chemical yields and diastereomeric ratios of the major syn-
products were moderate to good. The syn-selectivity was in agreement with the data reported in the 
literature. The presence of heteroatoms and para-halogenated arenes in the aromatic part of the 
imine afforded the best enantioselections (up to 99% ee). 
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Experimental Part 
General. N-Protected imines 2 were prepared according to the published methods.8 Anhydrous solvents 
were freshly distilled under an argon atmosphere and degasified by Freeze-Pump-Thaw methodology. 
Aldehydes were also distilled prior to use for the elaboration of the imino esters 1 and imines 2. Melting 
points were determined with a Reichert Thermowar hot plate apparatus and are uncorrected. Only the 
structurally most important peaks of the IR spectra (recorded whit a FT-IR 4100LE (JASCO) (PIKE 
MIRacle ATR) are listed. 1H NMR (300 MHz) and 13C NMR (75 MHz) spectra were obtained with a Bruker 
AC-300 by using CDCl3 as solvent and TMS as the internal standard, unless otherwise stated. Optical 
rotations were measured with a Perkin-Elmer 341polarimeter. HPLC analyses were performed with a 
JASCO-2000 series equipped with a chiral column (detailed for each compound in the main text) by using 
mixtures of n-hexane/isopropyl alcohol as the mobile phase at 25 ºC. Low-resolution electron impact (EI) 
mass spectra were obtained with a Shimadzu QP-5000 by injection or DIP, and high-resolution mass spectra 
were obtained with a Finnigan VG Platform or a Finnigan MAT 95S. Analitical TLC was performed on 
Schleicher & Schuell F1400/LS  254 silica gel plates and the spots were visualized under UV light (λ = 254 
nm). Merck silica gel 60 (0.040-0.063 mm) was used for flash chromatography. 
 
General procedure for the Mannich-type reaction. 
In a 10 ml vial covered by aluminum foil, was added AgOTf (1.54 mg, 0.006 mmol), phosphoramidite 18 
(3.24 mg, 0.006 mmol) and toluene (2 ml), and the mixture was stirred at room temperature for 1 h. 
Benzophenone imine derivative 1 (0.120 mmol) and N-tosylimine 2 (0.144 mmol) were added. The reaction 
was stirred 1 d at room temperature and the crude was analyzed by 1H RMN spectroscopy to determine the 
diastereomeric ratio, and then purified by flash chromatography (n-hexane:EtOAc; 15% of EtOAc), 
affording the products syn/anti-3. 
 
Methyl 2-[(diphenylmethylene)amino]-3-(4-methylphenylsulfonamide)-3-phenylpropanoate syn-3a + 
anti-3a:8k 42.9 mg; 70% yield; HPLC: (Daicel Chiralpak AD-H), hexane/i-PrOH 90/10, flow rate 1 ml/min, 
tR: 23.7 min (syn), 36.4 min (anti), 42.2 min (anti) and 45 min (syn), 254 nm; IR νmax: 3297, 1736, 1628, 
1328, 1157 cm-1; 1H-RMN δH: 2.27 (s, 3H, Meanti), 2.34 (s, 3H, Mesyn), 3.49 (s, 3H, OMeanti), 3.51 (s, 3H, 
OMesyn), 4.14 (d, J = 2.2 Hz, 1Hsyn), 4.36 (d, J = 5.9 Hz, 1Hanti), 4.71 (dd, J = 7.6, 5.8 Hz, 1Hanti), 5.16 (dd, J 
= 8.4, 2.0 Hz, 1Hsyn), 5.78 (d, J = 7.1 Hz, NHanti), 6.37 (t, J = 8.4 Hz, 2Hsyn + NHsyn); 6.88-7.72 (m, 19Hsyn, 
19Hanti, Ar H); 13C-RMN δC: 21.4 (Me), 52.3 (CsynNH), 59.4 (CsynN=), 60.0 (CantiN=), 69.4 (OMeanti), 69.9 
(OMesyn), 126.8, 126.9, 127.1, 127.3, 127.4, 128.1, 128.3, 128.6, 128.9, 129.2, 130.9, 135.5, 138.2, 138.5, 
139.0, 142.8 (ArC), 169.6syn, 173.1syn (CO, CN). MS (EI) m/z (%): 512 (0.12), 259 (12), 194 (40), 155 (33), 
91 (100), 65 (10). 
 
Methyl 2-[(diphenylmethylene)amino]-3-(4-methylphenylsulfonamide)-3-(o-methylphenyl)propanoate 
syn-3b + anti-3b:8k 31.6 mg; 50% yield; HPLC: (Daicel Chiralpak AD-H), hexane/i-PrOH 85/15, flow rate 
1 ml/min, tR: 9.7 min (syn), 14.0 min (anti), 15.4 min (anti) and 19.9 min (syn), 254 nm; IR νmax: 2987, 
1725, 1334, 1265, 1159, 1093, 733, 700 cm-1; 1H-RMN δH: 1.97 (s, 3H, Meanti), 2.04 (s, 3H, Mesyn), 2.26 (s, 
3H, Meanti), 2.33 (s, 3H, Mesyn), 3.51 (s, 3H, OMesyn), 3.53 (s, 3H, OMeanti), 4.06 (d, J = 2.1 Hz, 1Hsyn), 4.31 
(d, J = 6.5 Hz, 1Hanti), 4.87 (d, J = 6.5 Hz, 1Hanti), 5.40 (dd, J = 8.5, 2.0 Hz, 1Hsyn), 6.21 (d, J = 7.5 Hz, 
2Hsyn), 6.42 (d, J = 8.4 Hz, NHsyn), 6.79-7.89 (m, 16Hsyn, 16Hanti, Ar H); 13C-RMN δC: 21.5 (Me), 52.4 
(CsynNH), 55.9 (CsynN=), 125.6, 126.5, 126.8, 127.0, 128.3, 128.5, 128.9, 129.2, 129.7, 130.1, 132.4, 




syn-3c + anti-3c:8k 36.1 mg; 55% yield; HPLC: (Daicel Chiralpak IB), hexane/i-PrOH 95/5, flow rate 1 
ml/min, tR: 17.4 min (syn) and 21.7 min (syn), 254 nm; IR νmax: 1739, 1597, 1443, 1332, 1159, 1088, 764, 
697 cm-1; 1H-RMN δH: 2.23 (s, 3H, Meanti), 2.36 (s, 3H, Mesyn), 3.44 (s, 3H, OMesyn), 3.47 (s, 3H, OMeanti), 
4.30 (d, J = 2.1 Hz, 1Hsyn), 4.48 (d, J = 5.9 Hz, 1Hanti), 4.85 (t, J = 5.8 Hz, 1Hanti), 5.54 (dd, J = 8.3, 2.0 Hz, 
1Hsyn), 6.28 (d, J = 7.3 Hz, 2Hsyn), 6.32 (d, J = 6.0 Hz, NHsyn), 6.46 (d, J = 8.3 Hz, NHanti), 6.78-7.73 (m, 
18Hsyn, 18Hanti, Ar H); 13C-RMN δC: 21.4 (Me), 52.0 (CsynNH), 56.2 (CsynN=), 66.6 (OMesyn), 126,7, 127.1, 
127.5, 127.9, 128.3, 128.6, 129.0, 129.3, 129.7, 130.0, 130.9, 132.4, 135.3, 136.4, 137.8, 138.5, 143.0, 




syn-3d + anti-3d:8k 47.6 mg; 67% yield; HPLC: (Daicel Chiralpak OD-H), hexane/i-PrOH 90/10, flow rate 
0.6 ml/min, tR: 15.2 min (syn), 16.9 min (anti), 22.7 min (anti) and 37.8 min (syn), 254 nm. IR νmax: 3285, 
2987, 1738, 1333, 1159, 1081, 765, 697 cm-1; 1H-RMN δH: 2.24 (s, 3H, Meanti), 2.36 (s, 3H, Mesyn), 3.45 (s, 
3H, OMeanti), 3.46 (s, 3H, OMesyn), 4.33 (d, J = 2.1 Hz, 1Hsyn), 4.49 (d, J = 5.7 Hz, 1Hanti), 4.80 (t, J = 5.5 
Hz, 1Hanti), 5.50 (dd, J = 8.2, 2.0 Hz, 1Hsyn), 6.26 (d, J = 6.7 Hz, 2Hsyn), 6.39 (d, J = 8.4 Hz, NHanti), 6.49 (d, 
J = 8.2 Hz, NHsyn), 6.79-7.87 (m, 18Hsyn, 18Hanti, Ar H); 13C-RMN δC:  21.4 (Me), 51.9 (CsynNH), 58.4 
(CsynN=), 66.5 (OMesyn), 126.7, 127.2, 127.3, 127.5, 127.7, 128.0, 128.6, 129.0, 129.3, 129.7, 130.0, 130.9, 
132.6, 135.3, 138.5, 143.1, 169.8syn, 172.6syn (CO, CN); MS (EI) m/z (%): 591 (0.36), 258 (38), 194 (36), 
165 (11), 155 (33), 91 (100), 65 (10). 
 
Methyl 2-[(diphenylmethylene)amino]-3-(4-methylphenylsulfonamide)-3-(m-chlorophenyl)propanoate 
syn-3e + anti-3e:8d 27.6 mg; 42% yield; HPLC: (Daicel Chiralpak AD), hexane/i-PrOH 90/10, flow rate 1 
ml/min, tR: 40.8 min (syn) and 78.1 min (syn), 254 nm. IR νmax: 2987, 1739, 1657, 1597, 1159, 1076, 701, 
665 cm-1; 1H-RMN δH: 2.30 (s, 3H, Meanti), 2.36 (s, 3H, Mesyn), 3.50 (s, 3H, OMeanti), 3.51 (s, 3H, OMesyn), 
4.15 (d, J = 2.3 Hz, 1Hsyn), 4.42 (d, J = 5.4 Hz, 1Hanti), 4.78 (dd, J = 7.7, 5.5 Hz, 1Hanti), 5.16 (dd, J = 8.3, 
2.3 Hz, 1Hsyn), 5.77 (d, J = 7.7 Hz, NHanti), 6.44 (t, J = 8.4 Hz, 2Hsyn + NHsyn), 6.89-7.69 (m, 16Hsyn, 16Hanti, 
Ar H); 13C-RMN (75 MHz, CDCl3) δC: 21.4 (Me), 29.7, 52.5 (CsynNH), 57.4 (CsynN=), 69.5 (OMesyn), 123.0, 
126.6, 127.0, 128.3, 128.6, 128.9, 129.4, 129.5, 130.0, 131.2, 132.4, 134.6, 134.7, 143.2, 148.4, 148.6, 




propanoate syn-3f + anti-3f:8k 20.9 mg; 30% yield; HPLC: (Daicel Chiralpak AD-H), hexane/i-PrOH 
90/10, flow rate 0.8 ml/min, tR: 13.5 min (syn), 16.4 min (anti), 27.8 min (syn) and 30.5 min (anti), 254 nm; 
IR νmax: 3288, 2360, 1743, 1324, 1159, 1119, 1067, 700 cm-1; 1H-RMN δH: 2.29 (s, 3H, Meanti), 2.36 (s, 3H, 
Mesyn), 3.52 (s, 3H, OMeanti), 3.54 (s, 3H, OMesyn), 4.17 (d, J = 2.2 Hz, 1Hsyn), 4.43 (d, J = 5.5 Hz, 1Hanti), 
4.81 (dd, J = 7.6, 5.6 Hz, 1Hanti), 5.20 (dd, J = 8.3, 1.9 Hz, 1Hsyn), 5.83 (d, J = 7.6 Hz, NHanti), 6.39 (d, J = 
7.1 Hz, 2Hsyn), 6.46 (d, J = 8.3 Hz, NHsyn), 6.87-7.70 (m, 18Hsyn, 18Hanti, Ar H); 13C-RMN δC: 21.3 (Me), 
52.5 (CsynNH), 59.1 (CsynN=), 69.5 (OMesyn), 126.7, 127.1, 127.3, 128.2, 128.3, 128.5, 128.8, 128.9, 129.3, 
130.0, 131.2, 137.8, 138.1, 143.1, 143.2, 169.3syn, 173.6syn (CO, CN); MS (EI) m/z (%): 580 (0.25), 252 (10), 
194 (35), 165 (10), 155 (46), 91 (100), 65 (10). 
 
Methyl 2-[(diphenylmethylene)amino]-3-(4-methylphenylsulfonamide)-3-(p-nitrophenyl)propanoate 
syn-3g + anti-3g:8d 31.4 mg; 47% yield; HPLC: (Daicel Chiralpak OD-H), hexane/i-PrOH 85/15, flow rate 
0.6 ml/min, tR: 17.4 min (syn), 21.0 min (anti), 23.0 min (syn) and 39.1 min (anti), 254 nm; IR νmax: 3273, 
1734, 1624, 1519, 1344, 1159, 851, 697 cm-1; 1H-RMN δH: 2.28 (s, 3H, Meanti), 2.37 (s, 3H, Mesyn), 3.48 (s, 
3H, OMesyn), 3.49 (s, 3H, OMeanti), 4.18 (d, J = 2.2 Hz, 1Hsyn), 4.38 (d, J = 5.5 Hz, 1Hanti), 4.78 (dd, J = 7.5, 
5.6 Hz, 1Hanti), 5.20 (dd, J = 8.0, 2.1 Hz, 1Hsyn), 5.91 (d, J = 7.0 Hz, NHanti), 6.45 (d, J = 7.1 Hz, 2Hsyn), 6.51 
(d, J = 8.1 Hz, NHsyn), 6.82-8.12 (m, 18Hsyn, 18Hanti, Ar H); 13C-RMN δC: 21.4 (Mesyn), 25.3 (Meanti), 52.3 
(CantiNH), 52.5 (CsynNH), 58.9 (CsynN=), 59.2 (CantiN=), 64.4 (OMeanti), 69.2 (OMesyn), 123.2, 123.3, 126.6, 
127.0, 127.2, 127.8, 128.2, 128.3, 128.6, 128.7, 128.8, 128.9, 129.4, 131.3, 135.1, 137.7, 137.9, 143.4, 145.1, 
146.7, 147.1, 169.1syn, 169.4anti, 173.9syn (CO, CN); MS (EI) m/z (%): 557 (0.13), 194 (44), 165 (12), 155 
(36), 91 (100), 65 (10). 
 
Methyl 2-[(diphenylmethylene)amino]-3-(4-methylphenylsulfonamide)-3-(p-fluorophenyl)propanoate 
syn-3h + anti-3h:8e 30.6 mg; 48% yield; HPLC: (Daicel Chiralpak OD-H), hexane/i-PrOH 90/10, flow rate 
0.6 ml/min, tR: 13.4 min (syn), 14.8 min (anti), 17.1 min (anti) and 32.6 min (syn), 254 nm; IR νmax: 3289, 
2971, 1753, 1628, 1509, 1428, 1328, 1156, 1081, 736, 697 cm-1; 1H-RMN δH: 2.29 (s, 3H, Meanti), 2.36 (s, 
3H, Mesyn), 3.50 (s, 3H + 3H, OMesyn+anti), 4.12 (d, J = 2.3 Hz, 1Hsyn), 4.34 (d, J = 5.8 Hz, 1Hanti), 4.71 (dd, J 
= 7.1, 6.1 Hz, 1Hanti), 5.13 (dd, J = 8.1, 2.0 Hz, 1Hsyn), 5.80 (d, J = 7.5 Hz, NHanti), 6.42 (t, J = 7.5 Hz, 2Hsyn 
+ NHsyn), 6.74-7.90 (m, 18Hsyn, 18Hanti, Ar H); 13C-RMN δC: 21.4 (Me), 52.4 (CsynNH), 58.8 (CsynN=), 69.9 
(OMesyn), 114.9, 126.5, 126.8, 127.0, 128.2, 128.4, 128.9, 129.2, 129.7, 130.0, 131.0, 132.4, 138.0, 142.9, 
169.5syn, 173.4syn (CO, CN); MS (EI) m/z (%): 530 (0.32), 277 (10), 194 (37), 155 (35), 91 (100), 65 (10). 
 
Methyl 2-[(diphenylmethylene)amino]-3-(4-methylphenylsulfonamide)-3-(p-chlorophenyl)propanoate 
syn-3i + anti-i:8k 46.2 mg; 70% yield; HPLC: (Daicel Chiralpak OD-H), hexane/i-PrOH 90/10, flow rate 0.6 
ml/min, tR: 16.3 min (syn), 17.6 min (anti), 21.1 min (syn) and 37.4 min (anti), 254 nm; IR νmax: 3260, 2923, 
1754, 1597, 1288, 1157, 1088, 698, 662 cm-1; 1H-RMN δH: 2.30 (s, 3H, Meanti), 2.37 (s, 3H, Mesyn), 3.50 (s, 
3H + 3H, OMesyn+anti), 4.13 (d, J = 2.3 Hz, 1Hsyn), 4.35 (d, J = 5.7 Hz, 1Hanti), 4.69 (dd, J = 7.3, 5.8 Hz, 
1Hanti), 5.11 (dd, J = 8.3, 2.1 Hz, 1Hsyn), 5.79 (d, J = 7.6 Hz, NHanti), 6.41 (d, J = 9.1 Hz, NHsyn), 6.44 (d, J = 
7.4 Hz, 2Hsyn), 6.93-7.88 (m, 18Hsyn, 18Hanti, Ar H); 13C-RMN δC: 21.4 (Me), 52.4 (CsynNH), 58.9 (CsynN=), 
69.7 (OMesyn), 126.4, 126.8, 127.0, 128.2, 128.5, 128.9, 129.3, 129.7, 130.0, 131.1, 133.2, 135.3, 137.5, 




syn-3j + anti-3j:8h 24.8 mg; 35% yield; HPLC: (Daicel Chiralpak OD-H), hexane/i-PrOH 90/10, flow rate 
0.6 ml/min, tR:13.3 min (syn), 14.7 min (anti), 16.8 min (syn) and 29.7 min (anti), 254 nm; IR νmax: 3296, 
2971, 1754, 1630, 1328, 1157, 1075, 698 cm-1; 1H-RMN δH: 2.31 (s, 3H, Meanti), 2.37 (s, 3H, Mesyn), 3.50 (s, 
3H + 3H, OMesyn+anti), 4.13 (d, J = 2.3 Hz, 1Hsyn), 4.35 (d, J = 5.6 Hz, 1Hanti), 4.67 (dd, J = 7.5, 5.7 Hz, 
1Hanti), 5.08 (dd, J = 8.3, 2.1 Hz, 1Hsyn), 5.74 (d, J = 7.4 Hz, NHanti), 6.37 (d, J = 8.3 Hz, NHsyn), 6.45 (d, J = 
7.1 Hz, 2Hsyn), 6.85-7.69 (m, 18Hsyn, 18Hanti, Ar H); 13C-RMN δC: 21.4 (Me), 29.7, 52.4 (CsynNH), 58.9 
(CsynN=), 69.6 (OMesyn), 126.8, 127.1, 128.2, 128.5, 128.6, 128.9, 129.3, 130.0, 131.2, 138.2, 143.1, 
169.4syn; MS (EI) m/z (%): 591 (0.48), 194 (36), 155 (47), 91 (100), 65 (10). 
 
Methyl 2-[(diphenylmethylene)amino]-3-(4-methylphenylsulfonamide)-3-(2-furyl)propanoate syn-3k + 
anti-3k:8d 27.1 mg; 45% yield; HPLC: (Daicel Chiralpak AD), hexane/i-PrOH 90/10, flow rate 1 ml/min, tR: 
15.0 min (syn), 25.1 min (anti), 40.5 min (anti) and 65.5 min (syn), 254 nm; IR νmax: 3267, 2971, 2360, 
1739, 1277, 1158, 1075, 812, 700, 665 cm-1; 1H-RMN δH: 2.37 (s, 3H, Meanti), 2.37 (s, 3H, Mesyn), 3.52 (s, 
3H, OMeanti), 3.58 (s, 3H, OMesyn), 4.26 (d, J = 2.3 Hz, 1Hsyn), 4.58 (d, J = 4.3 Hz, 1Hanti), 5.24 (dd, J = 9.1, 
4.2 Hz, 1Hanti), 5.45 (dd, J = 8.8, 1.9 Hz, 1Hsyn), 6.35 (d, J = 9.1 Hz, NHanti), 6.75 (m, 4Hsyn + NHsyn), 7.03-
7.94 (m, 14Hsyn, 14Hanti, Ar H); 13C-RMN δC: 21.4 (Me), 52.5 (CsynNH), 55.9 (CsynN=), 69.9 (OMesyn), 
125.3, 126.2, 127.0, 128.2, 128.3, 128.5, 128.8, 129.1, 129.2, 130.1, 131.0, 132.4, 142.8; MS (EI) m/z (%): 
502 (0.56), 194 (40), 155 (23), 92 (11), 91 (100), 65 (10). 
 
Methyl 2-[(diphenylmethylene)amino]-3-(4-methylphenylsulfonamide)-3-(2-thienyl)propanoate syn-3l 
+ anti-3l:8h 28.0 mg; 45% yield; HPLC: (Daicel Chiralpak AS-H), hexane/i-PrOH 85/15, flow rate 1 
ml/min, tR: 15.3 min (syn) and 22.7 min (syn), 254 nm; IR νmax: 3269, 2357, 1742, 1572, 1329, 1156, 1089, 
812, 734, 700 cm-1; 1H-RMN δH: 2.34 (s, 3H, Meanti), 2.38 (s, 3H, Mesyn), 3.51 (s, 3H + 3H, OMesyn+anti), 
4.37 (d, J = 2.5 Hz, 1Hsyn), 4.47 (d, J = 6.0 Hz, 1Hanti), 5.20 (dd, J = 9.3, 2.0 Hz, 1Hsyn), 6.07 (dd, J = 2.5, 0.8 
Hz, 1Hsyn), 6.15 (dd, J = 3.2, 1.9 Hz, 1Hsyn), 6.22 (d, J = 9.3 Hz, 1Hsyn), 6.75 (d, J = 1.6 Hz, 1Hsyn), 6.77 (d, J 
= 1.2 Hz, NHsyn), 7.08-7.89 (m, 14Hsyn, 14Hanti, Ar H); 13C-RMN δC: 21.4 (Me), 52.5 (CsynNH), 55.9 
(CsynN=), 69.9 (OMesyn), 107.8, 110.4, 125.3, 125.5, 126.2, 126.4, 127.0, 127.9, 128.1, 128.5, 128.8, 129.0, 
129.2, 129.3, 129.7, 131.0, 136.7, 139.0, 162.2, 169.3syn, 173.8syn (CO, CN); MS (EI) m/z (%): 518 (0.47), 
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